- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.08. | Supernus, Individor merge to beef up brain drug portfolio | ||
| 31.07. | Novo setback casts doubt on a new way to treat heart disease | ||
| 31.07. | Sanofi to 'rebuild trust' with Regeneron; Apnimed adds to string of 'upsized' biotech IPOs | ||
| 30.07. | Replimune melanoma drug wins support of FDA panel | ||
| 30.07. | Alnylam plunges as earnings deliver 'one-two punch' | ||
| 30.07. | FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices | ||
| 30.07. | J&J nabs option to buy 'in vivo' CAR-T maker Sail for nearly $2.6B | ||
| 30.07. | Capricor Duchenne cell therapy voted down by FDA panel | ||
| 29.07. | MapLight CEO on what investors missed in the biotech's schizophrenia data | ||
| 29.07. | Caldera, Vidya add to recent flurry of biotech mergers | ||
| 29.07. | AbCellera, Vertex partner on next-gen T-cell engagers | ||
| 29.07. | FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer's data | ||
| 29.07. | Earnings roundup: Biogen's 'resiliency,' AstraZeneca's growth pitch and GSK's oncology push | ||
| 28.07. | GSK prepares for patent cliff with $2.5B cost-cutting plan | ||
| 28.07. | The FDA was all in on AI. Will that change? | ||
| 28.07. | An eye drug biotech banks $118M and stocks its executive suite | ||
| 27.07. | MapLight dives despite positive data for schizophrenia drug | ||
| 27.07. | Argenx to acquire Forte in $2.2B deal for 'differentiated' immune drug | ||
| 27.07. | FDA scientists question Capricor data; Legend CEO steps down | ||
| 27.07. | Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO | ||
| 27.07. | [Podcast] (Season 2) The Progress Profile: Alzheimer's Research in Focus | ||
| 27.07. | From confidence to capital: Positioning biotech for the next growth cycle | ||
| 24.07. | Sanofi halts development of troubled immune drug in eczema | ||
| 24.07. | Novo escalates legal fight with Lilly; J&J reinforces 'dominance' in multiple myeloma | ||
| 23.07. | Lilly, with new data, to seek FDA approval of obesity drug retatrutide |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.